Praluent vs Repatha
Side-by-side cost comparison based on Medicare Part D data
Praluent
Alirocumab
Manufactured by Regeneron/Sanofi
Repatha
Evolocumab
Manufactured by Amgen
Praluent costs 7% less per claim than Repatha ($706.00 vs $757.00). A generic version of Praluent is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Praluent | Repatha |
|---|---|---|
| Avg Cost Per Claim | $706.00 | $757.00 |
| Total Medicare Spending | $876.0M | $2.6B |
| Total Beneficiaries | 148,000 | 398,000 |
| Total Claims | 1,240,000 | 3,420,000 |
| Annual Cost/Patient | $5,919.00 | $6,505.00 |
| Year-over-Year Change | +15.3% | +24.6% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Aug 27, 2029 |
| Manufacturer | Regeneron/Sanofi | Amgen |
| Condition | High Cholesterol | High Cholesterol |
| Generic Name | Alirocumab | Evolocumab |
Praluent vs Repatha: What the Data Shows
Praluent (Alirocumab) and Repatha (Evolocumab) are both used to treat high cholesterol. Based on Medicare Part D data, Praluent costs $706.00 per claim, which is 7% less than Repatha at $757.00 per claim.
Medicare spent $876.0M on Praluent and $2.6B on Repatha. In terms of patient reach, Repatha serves more beneficiaries (398,000 vs 148,000).
Year-over-year spending changed +15.3% for Praluent and +24.6% for Repatha. Praluent saw significant spending growth, suggesting increased utilization or price increases. Repatha saw significant spending growth, suggesting increased utilization or price increases.
Praluent has a generic available, while Repatha remains brand-only until its patent expires Aug 27, 2029.
Frequently Asked Questions
Praluent is cheaper at $706.00 per claim, compared to $757.00 for Repatha. That makes Praluent about 7% less expensive per claim based on Medicare Part D data.
Yes, both Praluent and Repatha are used to treat high cholesterol. Your doctor can help determine which medication is more appropriate for your specific situation.
Praluent has a generic version (Alirocumab) available, which is typically much cheaper. Repatha is currently brand-only, with patent expiring Aug 27, 2029.
Medicare Part D spent $876.0M on Praluent covering 148,000 beneficiaries, and $2.6B on Repatha covering 398,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.